Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423855 | 0.90 | GRM2 (0.33) | MGLLPDE10AJAK2JAK1 | |
| SCHEMBL24253550 | 0.87 | PDE10A (0.32) | MGLLMOGAT2PDE10A | |
| SCHEMBL30424152 | 0.87 | PDE10A (0.32) | MGLLMOGAT2PDE10A | |
| SCHEMBL24253731 | 0.87 | MOGAT2 (0.33) | MGLLMOGAT2PDE10A | |
| SCHEMBL24253900 | 0.87 | PDE10A (0.32) | MGLLMOGAT2PDE10A | |
| SCHEMBL24253630 | 0.86 | PDE10A (0.32) | MGLLMOGAT2PDE10A | |
| SCHEMBL30423848 | 0.86 | HCRTR1 (0.31) | MGLLPDE10A | |
| SCHEMBL24253544 | 0.86 | HCRTR1 (0.31) | MGLLPDE10A | |
| SCHEMBL24253628 | 0.85 | HCRTR1 (0.31) | PDE10A | |
| SCHEMBL30423610 | 0.85 | HCRTR1 (0.31) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | MGLL 4200/4885MOGAT2 4470/4885PDE10A 684/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | MGLL 4200/4885MOGAT2 4470/4885PDE10A 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.